Algenpantucel-L Immunotherapy + Standard Therapy Shows Promise in Pancreatic Cancer

Share this content:

(ChemotherapyAdvisor) – Adding algenpantucel-L immunotherapy to standard adjuvant treatment may improve survival in patients undergoing R0/R1 resection for pancreatic cancer, results of a Phase 2 study presented at the Society for Surgery of the Alimentary Tract, part of Digestive Disease Week, in San Diego May 22 has found.

The open-label, dose-finding, multi-institutional study enrolled 70 patients; median age was 62 years and 47% were female. A total of 81% were lymph node positive. Median tumor size was 3.2cm (range, 2–15cm; 25% >4cm) and 17% had a postoperative CA19-9 ≥180U/mL. Patients received algenpantucel-L 100million or 300million cells/dose and gemcitabine + 5-fluourouacil chemoradiation.

Algenpantucel-L comprises irradiated, live, allogenic human pancreatic cells expressing the enzyme α1,3 galactosyl transferase (α-CT), the major barrier to xenotransplantation from lower mammals to humans, the study investigators noted. “Up to 2% of circulating human antibodies are directed against the α-CT epitope of algenpantucel-L and are the proposed mechanism of initiating the anti-tumor immune response.”

At a median follow-up of 21 months, patients had received a mean of 12 doses (range, 1–14 doses) of algenpantucel-L immunotherapy plus standard adjuvant therapy. The primary endpoint of disease-free survival was a median of 14.3 months in 63% of patients.

Subgroup analysis showed that patients receiving 300million cells/dose had a longer 12-month disease-free survival than those receiving 100million cells/dose, 81% vs 52%, respectively (P=0.02). Overall survival, a secondary end point, was 86% at 1 year for the entire cohort. The subgroup receiving 300million cells/dose tended toward a longer overall survival, 96%, than the subgroup receiving 100million cells/dose (80%; P=0.053).

Algenpantucel-L was well tolerated; there were no grade 4 or 5 adverse events and 9 grade 3 adverse events directly or possibly related to immunotherapy. The most common adverse events were injection-site pain and induration.

A randomized Phase 3 trial of up to 18 immunizations of 300 million immunotherapy cells of algenpantucel-L plus standard gemcitabine and 5-FU chemoradiation vs. gemcitabine and 5-FU chemoradiation alone is currently enrolling; anticipated enrollment is 700 patients.

Algenpantucel-L, developed by NewLink Genetics Corporation, Ames, IA, is also known as HyperAcute Pancreas Immunotherapy and HAPa-1 and HAPa-2 immunotherapy components. The product candidate has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration.


Clinical Trial

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs